Literature DB >> 32530288

Heptamethine Cyanine Dye Mediated Drug Delivery: Hype or Hope.

Peter J Choi1, Thomas I H Park2,3, Elizabeth Cooper1,2,3, Mike Dragunow2,3, William A Denny1, Jiney Jose1.   

Abstract

This review covers the application of heptamethine cyanine dye (HMCD) mediated drug delivery. A relatively small number of HMCDs possess tumor targeting abilities, and this has spurred interest from research groups to explore them as drug delivery systems. Their tumor selectivity is primarily attributed to their uptake by certain isoforms of organic anion transporting polypeptides (OATPs) which are overexpressed in cancer tissues, although there are other possible mechanisms for the observed selectivity still under investigation. This specificity is confirmed using various cancer cell lines and is accompanied by moderate cytotoxicity. Their retention in tumor tissue is facilitated by the formation of albumin adducts as revealed by published mechanistic studies. HMCDs are also organelle selective dyes with specificity toward mitochondria and lysosomes, and with absorption and emission in the near-infrared region. This makes them valuable tools for biomedical imaging, especially in the field of fluorescence-guided tumor surgery. Furthermore, conjugating antitumor agents to HMCDs is providing novel drugs that await clinical testing. HMCD development as theranostic agents with dual tumor targeting and treatment capability signals a new approach to overcome drug resistance (mediated through evasion of efflux pumps) and systemic toxicity, the two parameters which have long plagued drug discovery.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32530288     DOI: 10.1021/acs.bioconjchem.0c00302

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  8 in total

1.  Heptamethine Cyanine Dye MHI-148-Mediated Drug Delivery System to Enhance the Anticancer Efficiency of Paclitaxel.

Authors:  Athira Raveendran; Suchithra Poilil Surendran; Jinhui Ser; Khurshed Alam; Hoonsung Cho; Yong Yeon Jeong
Journal:  Int J Nanomedicine       Date:  2021-10-21

2.  Fluorescent PARP Inhibitors Applied To Intracranial Glioblastoma: Accumulation and Persistence In Vivo.

Authors:  Zhe Gao; Zhen Yang; Zheng Li; Kevin Burgess
Journal:  ACS Med Chem Lett       Date:  2022-05-06       Impact factor: 4.632

Review 3.  Polymethine dyes for PDT: recent advances and perspectives to drive future applications.

Authors:  Degnet Melese Dereje; Carlotta Pontremoli; Maria Jesus Moran Plata; Sonja Visentin; Nadia Barbero
Journal:  Photochem Photobiol Sci       Date:  2022-02-01       Impact factor: 3.982

Review 4.  Fluorescent kinase inhibitors as probes in cancer.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Chem Soc Rev       Date:  2021-07-22       Impact factor: 60.615

5.  Comparison of cRGDfK Peptide Probes with Appended Shielded Heptamethine Cyanine Dye (s775z) for Near Infrared Fluorescence Imaging of Cancer.

Authors:  Rananjaya S Gamage; Dong-Hao Li; Cynthia L Schreiber; Bradley D Smith
Journal:  ACS Omega       Date:  2021-10-30

6.  Conjugation of Palbociclib with MHI-148 Has an Increased Cytotoxic Effect for Breast Cancer Cells and an Altered Mechanism of Action.

Authors:  Peter Jaein Choi; Petr Tomek; Moana Tercel; Jóhannes Reynisson; Thomas In Hyeup Park; Elizabeth Alexandra Cooper; William Alexander Denny; Jiney Jose; Euphemia Leung
Journal:  Molecules       Date:  2022-01-27       Impact factor: 4.411

Review 7.  The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors.

Authors:  Elizabeth Cooper; Peter J Choi; William A Denny; Jiney Jose; Mike Dragunow; Thomas I-H Park
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

8.  Molecular Tuning of IR-786 for Improved Tumor Imaging and Photothermal Therapy.

Authors:  Wonbong Lim; Jae Yong Byun; Gayoung Jo; Eun Jeong Kim; Min Ho Park; Hoon Hyun
Journal:  Pharmaceutics       Date:  2022-03-19       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.